Follow-up for people with sickle cell treated with gene therapy
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study is a long-term follow-up for people who already received gene therapy for sickle cell disease in a specific sponsor’s clinical trial. It helps researchers watch for long-term safety and outcomes over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your parent/guardian) can provide written consent for this study.
- You must have already been treated with the gene therapy drug product for sickle cell disease.
- Your treatment must have been in a bluebird bio-sponsored clinical study.
- There are no additional exclusion criteria listed for this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This long-term follow-up study monitors people with sickle cell disease or transfusion-dependent beta-thalassemia who have already received the gene-editing therapy EDIT-301. It helps researchers understand how safe and effective the treatment is over time.
This trial tests a gene therapy that uses a modified virus to deliver a healthy gene to your blood stem cells. It aims to help people with sickle cell disease produce normal red blood cells and reduce painful crises.
This trial tests a new gene therapy called KL003 for people with severe sickle cell disease. It aims to fix your own stem cells so they make healthy red blood cells, reducing pain crises. You may qualify if you've had at least four severe pain episodes in the last two years and have not responded well to hydroxyurea.
This trial tests a new gene therapy for sickle cell disease. It uses your own blood stem cells (collected from bone marrow) that are modified in a lab to help produce healthy red blood cells, then given back to you after a short chemotherapy. The goal is to reduce or stop severe complications like pain crises and lung problems.
This study looks at long-term health effects after curative treatments for sickle cell disease, such as bone marrow transplant. Your participation helps researchers understand what changes over time after treatment, and what might need monitoring or care.
This study uses one-on-one interviews to learn what families and clinicians need to make decisions about gene therapy for rare diseases. The goal is to create or improve decision tools that make gene therapy information easier to understand and act on.
Hear when a new Sickle Cell Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.